[Reassessment of drugs].
The usefulness of a product can vary considerably over the course of time. Nothing is more arduous than to have to re-evaluate a medication but nothing is more necessary. The Legal Information of market authorization can become obsolete and necessitate a re-evaluation, a harmonisation with the products of the same therapeutic class, in short, a re-writing. The notion of the level of classification of drug utility can vary: arrival of new products that are more efficacious, publication of negative data concerning the efficacity or security of one or more products of the class. The decision to include in the national re-emborsement scheme, the fixation of the level of re-emborsement, and the price of the product can vary. This necessary fluidity comes up against the unwieldy nature of the procedures that must be put in place in order to carry out a re-evaluation in the proper conditions and in not distorting them at the time of active competition of the drug companies.